Follow the Doximity, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Doximity, Inc. has published 166 reports. Market capitalisation: €4bn. The latest transaction was filed on 18 June 2026 (Attribution). Among the most active insiders: Wampler Kira Scherer. The full history is free.
Analysts rate Doximity, Inc. Buy (bullish), based on 19 analysts. Average price target: US$24.37.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 166 declarations
Doximity, Inc. is a U.S.-based company listed on the NYSE under the ticker DOCS, with headquarters in San Francisco, California, United States. Founded in 2010, the company has built a leading digital platform for U.S. medical professionals, especially physicians. From an investor perspective, Doximity sits at the intersection of healthcare, software, and data, making it more of a healthtech platform than a traditional biotech company. Its business model is centered on a verified clinical network and a set of digital tools designed to improve physician productivity, medical information access, and care coordination. The company’s core offering is a physician-focused digital ecosystem. Doximity enables collaboration among colleagues, access to medical news and research, career and on-call management, streamlined clinical documentation, and virtual patient visits. Over time, the platform has expanded beyond professional networking into workflow automation and clinical AI tools, which have become an increasingly important part of the product strategy and a major driver of engagement. In competitive terms, Doximity benefits from a strong installed base and a differentiated network effect. The company states that its network includes more than 85% of U.S. physicians across specialties and practice settings. That scale matters because the value of the platform rises with adoption, especially in healthcare, where verified identity, trust, and workflow integration are critical. Competitors include medical communication platforms, healthcare software vendors, telehealth providers, and newer AI-driven clinical reference tools. However, Doximity’s entrenched physician audience gives it a meaningful distribution advantage. Its main products and services include secure professional communication, telehealth video, workflow tools, and clinical AI features. A notable strategic move was the acquisition of Pathway Medical, a Montreal-based startup focused on evidence-based clinical reference and medical AI. That transaction underscores Doximity’s effort to deepen its clinical utility and broaden its product suite beyond networking. Geographically, the business remains highly concentrated in the United States, which is the company’s primary market and the core source of its user base and monetization. Although Doximity may leverage international capabilities through acquisitions or partnerships, its commercial focus is clearly domestic. Recent developments have been constructive: in its fiscal 2026 results released in May 2026, the company reported revenue growth, strong cash generation, and record usage of its workflow and AI tools. Management also highlighted new partnerships aimed at bringing Clinical AI to value-based care settings, reinforcing the view that Doximity is positioning itself as a mission-critical software layer for U.S. medical professionals.